Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

Market Cap	11.01B +132.1%
Revenue (ttm)	709.13M +33.7%
Net Income	64.21M
EPS	0.16
Shares Out	405.71M
PE Ratio	170.92
Forward PE	258.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,276,929
Average Volume	5,904,783
Open	25.70
Previous Close	25.94
Day's Range	25.67 - 28.70
52-Week Range	11.82 - 34.68
Beta	0.46
RSI	59.12
Earnings Date	Mar 20, 2026

About SHA:688319

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was founded in 2009 and is based in Chengdu, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 463
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688319

Financial Performance

In 2024, SHA:688319's revenue was 588.86 million, an increase of 18.69% compared to the previous year's 496.12 million. Earnings were 20.76 million, an increase of 18.24%.